While a direct link between ADAR1-mediated RNA editing and immunotherapy response in BC is not established, ADAR1’s role in enhancing neoantigen production and the IFN pathway suggests potential therapeutic targeting to improve immunotherapy outcomes (Figure 3). This evidence concerns the gene ADAR and breast cancer.